Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on patient enrolment and dosing of PEGPH20 in an ongoing phase II study (Study 202). The study is evaluating PEGPH20 as a first-line therapy for patients suffering from stage IV metastatic pancreatic cancer. Halozyme Therapeutics, Inc. (NASDAQ:HALO) shares after opening at $8.07 moved to $8.16 on last trade day and at the end of the day closed at $7.49. Company price to sales ratio in past twelve months was calculated as 16.95 and price to cash ratio as 12.99. Halozyme Therapeutics, Inc. (NASDAQ:HALO) showed a negative weekly performance of -35.38%.
Horizon Pharma, Inc. (NASDAQ:HZNP) announced that Skyepharma has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Horizon Pharma Inc. (NASDAQ:HZNP) shares fell -8.81% in last trading session and ended the day on $13.05. HZNP return on equity ratio is recorded as -340.20% and its return on assets is -80.60%. Horizon Pharma Inc. (NASDAQ:HZNP) yearly performance is 422.00%.
On April 7, 2014, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors of Celldex Therapeutics, Inc. (NASDAQ:CLDX), the Board adopted amended and restated by-laws to among other things replace with the plurality voting standard with a majority voting standard for uncontested elections of directors and eliminate the mandatory retirement age for directors. Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares moved down -8.12% in last trading session and was closed at $15.62, while trading in range of $15.51 – $17.20. Celldex Therapeutics, Inc. (NASDAQ:CLDX) year to date (YTD) performance is -35.48%.
Organovo Holdings, Inc. (AMEX:ONVO) released information to update investors on the results of its initial study of 3D breast tissues generated with its NovoGen MMX Bioprinter in breast cancer models. Organovo Holdings Inc. (NYSEMKT:ONVO) weekly performance is -4.68%. On last trading day company shares ended up $7.74. Organovo Holdings Inc. (NYSEMKT:ONVO) distance from 50-day simple moving average (SMA50) is -15.43%.
Leave a Reply